Rapamune Articles
Pfizer prevails in Rapamune patent dispute with Watson
1 February 2013
Santen's first-half income plummets 46%
8 December 2008
Novartis lines up aliskiren combos and cancer drugs to deal with Diovan's 2012 patent loss
24 November 2008
Japan stock market week to June 9, 2008
16 June 2008
Everolimus trial halted after early PFS gains
10 March 2008
Sirolimus impresses in Ph I wet AMD trial
3 March 2008
Cypher fares well vs bare metal stents
10 September 2007
Wyeth's 2nd-qtr net income climbs 12.5%
30 July 2007
New Rapamune dosing guide OKed by FDA
12 February 2007
Boston Sci's Taxus favorable TLR rate vs J&J's Cypher
22 January 2007
MacuSight initiates 30-patient sirolimus trial
6 November 2006
J&J's record 2nd-qtr 2006 sales boost profit 10%
24 July 2006
J&J's 1st-qtr 2006 earnings up 16.4%, but sales weak
24 April 2006
J&J's 4th-qtr 2005 sales drop 1.1% on low Rx
30 January 2006
Cordis announces positive Cypher stent data
12 September 2005
Guilford's Aggrastat sees strong results
23 May 2005
J&J's Cypher stent not superior to BS' Taxus
14 March 2005
Fen-phem charges gouge Wyeth results
7 February 2005
Wyeth's 2nd-qtr profit slips, but sales climb
26 July 2004
Wyeth posts 9% rise in 1st-qtr revenue
3 May 2004
Cordis gets FDA warning letter of GMP
12 April 2004
Stock Commentary - New York
26 January 2004
J&J 4th-qtr EPS up 35%, sales rise 20%
26 January 2004
J&J raises forecast on strong 3rd quarter
20 October 2003
Acquisition charges hit J&J 2nd-qtr results
21 July 2003
Rapamune gets new indication from FDA
21 April 2003
Stock Commentary - New York
7 April 2003
Boston Sci rolls out its Taxus coated stent
24 February 2003
Boston Sci gets Euro OK for paclitaxel stent
27 January 2003
Stock Commentary - New York
3 June 2002
New data on Novartis transplant drugs
6 May 2002
J&J's sirolimus stent cleared in Europe
22 April 2002
J&J Cypher stent keeps vessels clear at 2 years
25 March 2002
FDA panel votes against new Rapamune use
4 February 2002
New labeling for Wyeth's Rapamune?
7 January 2002
Boston Sci claims zero restenosis with stent
26 September 2001
Boston Sci claims zero restenosis with stent
25 September 2001
Cook's paclitaxel-coated stent eliminates restenosis
13 September 2001
Rapamune transplant drug approved in Canada
6 June 2001
Drug-coated stent blocks restenosis
2 January 2001
Wyeth's Rapamune gains CPMP backing
12 December 2000
Wyeth-Ayerst gains FDA OK for Rapamune tablet
31 August 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
Novartis loses battles over Neoral labeling and rapamycin patent
9 December 1999
Fujisawa earnings driven by Prograf; pipeline looking healthy
15 November 1999
Wyeth-Lederle withdraws RotaShield vaccine - updated story
21 October 1999
Stock Commentary New York
23 September 1999
AHP weathers the storm with first Rapamune approval
17 September 1999
AHP close to settling $3 billion lawsuits?
17 September 1999
American Home Products receives FDA approval for Rapamune
16 September 1999
FDA panel backs Wyeth's Rapamune
28 July 1999
Priority Review for Rapamune in USA
2 February 1999
Elan Completes Ziconotide Phase III In Neuropathic Pain
15 December 1998
AHP's Rapamune Improves 6-Month Graft Survival
16 July 1998
AHP Looks To Bright Future With New Products
30 April 1998
Roche's Zenapax Gets First Approval For Transplants
17 December 1997
Novartis Unveils Strong Product Pipeline
1 July 1997
FDA Panel Backs Cellcept For Acute Rejection
10 April 1995
New Drug Developments In Transplant Medicine
12 September 1994
SANDIMMUN SET FOR DECLINE, SAYS ANALYST
27 June 1994
Showing 1-83 of 83 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
